• Please log in or register to access this feature.

Open-Label Study on the Long-Term Efficacy, Safety, and Impact on Quality of Life of OROS Hydromorphone ER in Patients with Chronic Low Back Pain

  1. Mark Wallace MD1,*,
  2. John Thipphawong MD2

Article first published online: 28 SEP 2010

DOI: 10.1111/j.1526-4637.2010.00956.x

Issue

Pain Medicine

Pain Medicine

Volume 11, Issue 10, pages 1477–1488, October 2010

Additional Information

How to Cite

Wallace, M. and Thipphawong, J. (2010), Open-Label Study on the Long-Term Efficacy, Safety, and Impact on Quality of Life of OROS Hydromorphone ER in Patients with Chronic Low Back Pain. Pain Medicine, 11: 1477–1488. doi: 10.1111/j.1526-4637.2010.00956.x

Author Information

  1. 1

    Center for Pain Medicine, Department of Anesthesiology, University of California, San Diego School of Medicine, La Jolla, California

  2. 2

    Johnson and Johnson Pharmaceutical Research and Development, Fremont, California, USA

*Mark Wallace, MD, University of California, San Diego School of Medicine, 9300 Campus Point Drive, La Jolla, CA 92037-7650, USA. Tel: 858-657-6035; Fax: 858-657-6558; E-mail: mswallace@ucsd.edu

Publication History

  1. Issue published online: 28 SEP 2010
  2. Article first published online: 28 SEP 2010

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (518K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Aaron Yarlas, Kate Miller, Warren Wen, Bradley Dain, Shau Yu Lynch, Joseph V. Pergolizzi, Robert B. Raffa, Steven R. Ripa, A Randomized, Placebo-Controlled Study of the Impact of the 7-Day Buprenorphine Transdermal System on Health-Related Quality of Life in Opioid-Naïve Patients With Moderate-to-Severe Chronic Low Back Pain, The Journal of Pain, 2013, 14, 1, 14

    CrossRef

  2. 2
    Kate Miller, Aaron Yarlas, Warren Wen, Bradley Dain, Shau Yu Lynch, Michael J Brennan, Steven R Ripa, Buprenorphine transdermal system and quality of life in opioid-experienced patients with chronic low back pain, Expert Opinion on Pharmacotherapy, 2013, 14, 3, 269

    CrossRef

  3. 3
    Ute Richarz, Sandra Waechter, Rainer Sabatowski, Leszek Szczepanski, Heinrich Binsfeld, Sustained Safety and Efficacy of Once-Daily Hydromorphone Extended-Release (OROS® hydromorphone ER) Compared with Twice-Daily Oxycodone Controlled-Release Over 52 Weeks in Patients with Moderate to Severe Chronic Noncancer Pain, Pain Practice, 2013, 13, 1
    Direct Link:
  4. 4
    Srinivas R. Nalamachu, Michael Kutch, Martin E. Hale, Safety and Tolerability of Once-Daily OROS® Hydromorphone Extended-Release in Opioid-Tolerant Adults With Moderate-to-Severe Chronic Cancer and Noncancer Pain: Pooled Analysis of 11 Clinical Studies, Journal of Pain and Symptom Management, 2012, 44, 6, 852

    CrossRef

  5. 5
    Fábio Barbosa, Luciano Mantovani, Cássia V. Garcia, Andreas S. L. Mendez, Studies on Paliperidone in OROS Tablets: Extraction Procedure and Chromatographic Analysis, ISRN Chromatography, 2012, 2012, 1

    CrossRef

View Full Article (HTML) Get PDF (518K)